

# Randomised controlled trial to assess the efficacy of a comprehensive secondary prevention programme in primary care

<b>Submission date</b> 08/03/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 04/04/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 14/04/2008	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Carlos Brotons

**Contact details**  
Unit of Research  
Sardenya Primary Health Care Center  
Sardenya 466  
Barcelona  
Spain  
08025  
+34 935 67 43 80  
cbrotons@eapsardenya.net

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

N/A

## Study information

### Scientific Title

### Acronym

PREseAP

### Study objectives

A comprehensive programme on secondary prevention of cardiovascular diseases in primary care reduces rehospitalisation and mortality, and improves quality of life.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Prevention

### Participant information sheet

### Health condition(s) or problem(s) studied

Cardiovascular disease

### Interventions

Health Centres (clusters) are randomised to intervention or control group.

Intervention group (comprehensive programme in secondary prevention led by well-trained registered nurses):

Patient education and counselling, optimisation of the treatments according to CVD prevention guidelines (drugs, diet, exercise). The number of scheduled visits will be 9 (every 4 months).

**Control group:**

Patients in the control group will be assigned to conventional care. Number of visits: two (baseline assessment and final visit at the end of the trial).

Follow-up period: 3 years

Endpoints: combined of cardiovascular disease mortality and cardiovascular disease morbidity (including revascularisation)

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

1. Combination of total mortality
2. Cardiovascular fatal events
3. Cardiovascular non-fatal events

**Secondary outcome measures**

1. Total mortality
2. Cardiovascular fatal events
3. Cardiovascular non-fatal events
4. Quality of life measured with the 36-item short form health survey (SF-36) instrument

**Overall study start date**

01/01/2005

**Completion date**

31/12/2007

**Eligibility****Key inclusion criteria**

Patients are recruited from 42 primary health care centres from eight different regions of Spain (2100 patients are expected to be recruited).

**Inclusion Criteria:**

Males and females below 86 years, diagnosed with coronary heart disease (CHD), stroke or peripheral vascular disease in the last year.

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

2100

**Key exclusion criteria**

1. Patients diagnosed with cardiovascular disease (CVD) before the year 2004
2. Unstable patients (post myocardial infarction [MI] angina of less than 28 days after discharge, ventricular arrhythmias in the last six months)
3. Subarachnoid haemorrhage, cerebral embolisms secondary to valve disease
4. Patients with concomitant serious chronic disease (cancer, chronic renal failure, etc.)
5. Patients with poor mental function or any other reason to expect that the patient may have difficulty in complying with the requirements of the study

**Date of first enrolment**

01/01/2005

**Date of final enrolment**

31/12/2007

**Locations****Countries of recruitment**

Spain

**Study participating centre****Unit of Research**

Barcelona

Spain

08025

**Sponsor information****Organisation**

Sardenya Primary Care Center (in collaboration with the Catalan Foundation Institute of Pharmacology) (Spain)

**Sponsor details**

Sardenya 466

Barcelona

Spain

08025

+34 935 67 43 80

cbrotens@eapsardenya.net

**Sponsor type**

Hospital/treatment centre

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Carlos III Health Institute of the Spanish Ministry of Health and Consumption (Fondo de Investigaciones Sanitarias - Instituto de Salud Carlos III-Ministerio de Sanidad y Consumo) (Spain) (ref: PI031421)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	01/03/2008		Yes	No